CRIS Current Research Information System

DE GIGLIO, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.203
NA - Nord America 1.921
EU - Europa 1.526
SA - Sud America 210
AF - Africa 144
OC - Oceania 2
Totale 8.006
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.867
VN - Vietnam 1.226
SG - Singapore 1.036
CN - Cina 977
IT - Italia 621
HK - Hong Kong 335
NL - Olanda 194
IN - India 163
KR - Corea 156
BR - Brasile 151
DE - Germania 128
SE - Svezia 93
FR - Francia 85
FI - Finlandia 80
GB - Regno Unito 69
IE - Irlanda 69
JP - Giappone 58
JO - Giordania 52
CI - Costa d'Avorio 43
CH - Svizzera 34
PH - Filippine 34
RU - Federazione Russa 34
TH - Thailandia 30
ID - Indonesia 28
CA - Canada 26
TG - Togo 26
BG - Bulgaria 23
AR - Argentina 22
MX - Messico 22
BD - Bangladesh 19
IQ - Iraq 19
PL - Polonia 18
ZA - Sudafrica 18
AT - Austria 17
ES - Italia 17
SC - Seychelles 15
NG - Nigeria 12
TR - Turchia 12
TW - Taiwan 10
EC - Ecuador 9
CL - Cile 8
PK - Pakistan 8
UA - Ucraina 8
VE - Venezuela 7
BE - Belgio 6
CO - Colombia 6
EG - Egitto 6
SA - Arabia Saudita 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
DZ - Algeria 5
KE - Kenya 5
LT - Lituania 5
MY - Malesia 5
AZ - Azerbaigian 4
GR - Grecia 4
OM - Oman 4
KZ - Kazakistan 3
PY - Paraguay 3
TN - Tunisia 3
AL - Albania 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
DK - Danimarca 2
HR - Croazia 2
IL - Israele 2
JM - Giamaica 2
LU - Lussemburgo 2
LY - Libia 2
MA - Marocco 2
NP - Nepal 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
SO - Somalia 2
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GH - Ghana 1
GM - Gambi 1
IS - Islanda 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
MT - Malta 1
NI - Nicaragua 1
PT - Portogallo 1
SI - Slovenia 1
SN - Senegal 1
SR - Suriname 1
SV - El Salvador 1
UY - Uruguay 1
Totale 8.006
Salva come PNG Salva come JPEG
Città #
Singapore 702
Ho Chi Minh City 333
Ashburn 327
Hong Kong 322
Hefei 315
Hanoi 281
San Jose 235
Santa Clara 208
Seoul 138
Beijing 135
Bologna 107
Dallas 105
Boardman 85
Milan 73
Dublin 68
Hyderabad 66
Council Bluffs 60
Chandler 59
Los Angeles 51
Amman 50
Helsinki 48
Lauterbourg 45
Haiphong 44
Abidjan 43
Seattle 43
Tokyo 40
Da Nang 33
Dong Ket 30
Munich 30
New York 30
Rome 30
Bengaluru 28
Redondo Beach 27
Lomé 26
Bern 23
Biên Hòa 23
Sofia 23
Turin 23
Cinquefrondi 22
Frankfurt am Main 22
Quận Bình Thạnh 21
Shanghai 21
Buffalo 20
Fairfield 20
Ha Long 19
Jakarta 19
Princeton 19
Turku 18
Southend 17
Visakhapatnam 17
Guangzhou 16
Hải Dương 16
Modena 16
Nuremberg 16
São Paulo 16
Woodbridge 16
Houston 15
Messina 15
Ninh Bình 15
Bắc Ninh 14
Chicago 13
Amsterdam 12
Bắc Giang 12
Falkenstein 12
Johannesburg 12
Lappeenranta 12
Tianjin 12
London 11
Warsaw 11
Abeokuta 10
Cambridge 10
Montreal 10
Orem 10
Redmond 10
Vienna 10
Wilmington 10
Can Tho 9
Chongqing 9
Mexico City 9
Poplar 9
Quận Một 9
Tongling 9
Atlanta 8
Nha Trang 8
Stockholm 8
The Dalles 8
Xi'an 8
Điện Bàn 8
Cesena 7
Elk Grove Village 7
Manila 7
Moncalieri 7
Phoenix 7
Phủ Lý 7
San Diego 7
Thái Nguyên 7
Vinh 7
Zhengzhou 7
Bangkok 6
Brussels 6
Totale 5.060
Salva come PNG Salva come JPEG
Nome #
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 270
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 257
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 218
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 198
Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report 198
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 195
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 189
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 182
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) 177
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience 165
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 164
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 159
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 157
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors 157
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 156
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond 148
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 142
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) 139
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System 131
Advanced non-small-cell lung cancer: how to manage non-oncogene disease 129
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks 128
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians 127
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients 126
A Podcast on Pre- or Perioperative Chemoimmunotherapy for Stage III Non-Small Cell Lung Cancer: Shared Agreement from the Thoracic Surgeon and Oncologist Perspectives 125
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? 125
Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors 122
Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer 120
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report 120
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report 115
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis 111
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis 111
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib 109
An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances 108
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 106
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study 100
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis 99
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 98
Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach 95
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis 87
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review 86
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy 84
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies 83
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 80
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 78
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) 74
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 73
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities 73
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 71
Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (Nsclc) patients under immune-checkpoint inhibitors (ici) 70
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Rationale, evidence and place in therapy 70
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database 69
IMpower 132: Is the Second Exception to the Rule No Longer an Exception? 66
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 62
Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis 61
Primary angiosarcoma of the kidney: Case report and comprehensive literature review 61
Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics 60
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 60
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy 59
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience 57
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations 54
Carboplatin, nab-paclitaxel plus atezolizumab in Impower 130 trial: New weapons beyond controversies 51
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 51
Antibody–drug conjugates for lung cancer in the era of personalized oncology 50
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation 50
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program 49
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer 47
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis 47
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 45
Ductal breast carcinoma metastatic to the stomach resembling primary linitis plastica in a male patient 44
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 42
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 40
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 40
Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] (ESMO Open (2021) 6(2), (S205970292100034X), (10.1016/j.esmoop.2021.100078)) 39
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 38
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50% 36
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC 36
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression 36
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5) 36
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort 36
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 35
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer 34
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study 32
Efficacy and Safety of TROP-2-Targeting Antibody–Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data 29
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 29
Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort—the smile study 29
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 27
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 26
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 25
Letter Re: Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations 20
Totale 8.213
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.142
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.142
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202164 0 0 0 0 0 0 0 0 0 2 3 59
2021/2022174 3 2 1 4 8 6 0 37 20 10 53 30
2022/2023575 26 40 19 27 77 46 12 49 162 37 28 52
2023/2024395 36 47 26 25 23 73 9 62 16 25 39 14
2024/20252.140 113 137 131 135 302 113 214 74 55 217 172 477
2025/20264.796 638 794 419 418 361 221 449 181 967 348 0 0
Totale 8.213